Avricore Health Announces $1.25 Million Financing

• Avricore Health Inc. announced a non-brokered private placement of up to 25,000,000 units at $0.05 per unit on May 20, 2026.
• The offering aims to raise gross proceeds of up to $1,250,000 CAD (implied based on Canadian residency eligibility).
• Proceeds are designated for the expansion of the HealthTab™ network and general working capital purposes.
• Each unit consists of one common share and one half transferable share purchase warrant.
• Warrant terms include an exercise price of $0.10 per common share with a 24-month expiry from closing.
• Finder's fees may be paid up to 7% cash and 7% broker warrants on a portion of the placement.
• The offering is open to accredited investors and shareholders resident in Canada as of May 19, 2026.
• Certain directors and officers are expected to participate in this related party transaction.

• Dilution Risk: The issuance of 25 million units represents significant dilution relative to the current share base (exact count undisclosed), priced at $0.05 against a recent market price of $0.06. This discount signals potential liquidity pressure or management's belief that the stock is overvalued by the public market.
• Runway Extension: The capital raise provides necessary working capital to execute the UK expansion roadmap outlined in April 2026, targeting profitability by Q3 2027. Without this financing, the company risks cash flow constraints before reaching its profitability milestone.
• Sentiment Impact: Discount financings at or near recent lows often suppress stock price sentiment as they indicate a lack of organic growth funding or inability to raise capital at higher valuations. The market may view this as a "cash burn" confirmation rather than a strategic win.
• Warrant Overhang: New warrants with a $0.10 strike price add future selling pressure potential if the stock rallies significantly above current levels, capping upside momentum in the short term.

• Company: Avricore Health Inc. is a healthcare technology company focused on point-of-care testing (POCT).
• Flagship Project: HealthTab™ platform, an integrated solution combining instruments, cloud software, standardized workflows, training, and support for community pharmacies.
• Development Status: Currently expanding from North East London pilot to broader UK NHS market; targeting 500+ active locations by mid-2027.
• Operational Milestones: Completed 3,500+ patient screenings in London; achieved monthly per-location testing averages 10x higher than previous Canadian operations.
• Strategic Partnerships: Collaboration with Barts Health NHS Trust and British Heart Foundation for cardiovascular screening and inclisiran injection pilots.